Orsini's Exclusive Partnership with Ionis for Groundbreaking DAWNZERA Medication Orsini has been named the exclusive specialty pharmacy partner for Ionis Pharmaceuticals' new drug, DAWNZERA, aimed at treating hereditary angioedema.

Orsini's Exclusive Partnership with Ionis for Groundbreaking DAWNZERA Medication #United_States #Elk_Grove_Village #Ionis_Pharmaceuticals #Orsini_Pharmacy #DAWNZERA

🔎 Spotted in Molecular Therapy: Methods & Clinical Development!
Researchers from @umich.edu and #Ionis_Pharmaceuticals used DSHB's anti-C-peptide [GN-ID4] and anti-NKX6-1 [F55A12] mAbs in a study on the use of anti-TNF-α nanoparticles to protect stem-cell-derived islet transplants.

PANTHERx® Rare Collaborates with Ionis for TRYNGOLZA™ Distribution, a Milestone in Rare Disease Treatment PANTHERx® Rare has partnered with Ionis Pharmaceuticals to distribute TRYNGOLZA™, the first FDA-approved treatment for FCS, enhancing patient access.

PANTHERx® Rare Collaborates with Ionis for TRYNGOLZA™ Distribution, a Milestone in Rare Disease Treatment #United_States #Pittsburgh #Ionis_Pharmaceuticals #Tryngolza #PANTHERx_Rare

Groundbreaking FDA Approval: TRYNGOLZA™ Becomes First Treatment for Familial Chylomicronemia Syndrome Ionis Pharmaceuticals celebrates the FDA approval of TRYNGOLZA™, the first-ever treatment for adultswith familial chylomicronemia syndrome, transforming patient lives by reducing triglyceride levels significantly.

Groundbreaking FDA Approval: TRYNGOLZA™ Becomes First Treatment for Familial Chylomicronemia Syndrome #United_States #Carlsbad,_California #TRYNGOLZA™ #Olezarsen #Ionis_Pharmaceuticals